Abeona Therapeutics

ABEO

Cleveland, United States

abeonatherapeutics.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ABEO · Stock Price

USD 5.77+1.32 (+29.66%)

Market Cap: $329.9M

Historical price data

Overview

Abeona Therapeutics has successfully transitioned to a commercial-stage company with the launch of ZEVASKYN®, while advancing a pipeline of novel gene therapies for rare diseases with high unmet need. Its strategy is built on a proprietary AIM™ vector platform designed for enhanced delivery and efficacy, and is vertically integrated with internal manufacturing capabilities. The company is focused on inherited retinal diseases and neurological disorders, with key partnered programs in Sanfilippo Syndrome and Rett Syndrome. Abeona's mission is to deliver transformative, one-time treatments, aiming to make cures the new standard of care.

Inherited Retinal DiseasesNeurological Disorders

Technology Platform

The AIM™ (Abeona Integration Machine) Vector Platform is a proprietary engineered AAV vector system designed to enhance transduction efficiency, tissue specificity, and reduce immunogenicity for improved gene therapy delivery.

Pipeline

9 drugs in pipeline4 in Phase 3

Drug	Indication	Stage
ofloxacin + MSI-78	Diabetic Foot Ulcers	Phase 3
EB-101	Epidermolysis Bullosa	Phase 3
ofloxacin + MSI-78	Diabetic Foot Ulcers	Phase 3
EB-101 Surgical application of RDEB wounds	Epidermolysis Bullosa	Phase 3
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)	Onychomycosis	Phase 2

Opportunities

The commercial launch of ZEVASKYN® provides a critical revenue base and commercial proof-of-concept.

The proprietary AIM™ platform, if clinically validated, could generate a pipeline of best-in-class gene therapies for high-value rare diseases, while in-house manufacturing offers strategic control and potential cost advantages.

Risk Factors

Key risks include clinical failure of the entirely preclinical internal pipeline, commercial underperformance of ZEVASKYN®, future dilutive financings, and the high fixed costs and operational complexity associated with running an in-house gene therapy manufacturing plant.

Competitive Landscape

Abeona competes in the crowded gene therapy space for inherited retinal diseases against companies like Spark Therapeutics/Roche, and in neurological disorders through its partners. Its differentiation hinges on the performance of its AIM™ platform and its vertically integrated model with internal manufacturing capabilities.